==== Front Healthcare (Basel) Healthcare (Basel) healthcare Healthcare 2227-9032 MDPI 33255184 10.3390/healthcare8040511 healthcare-08-00511 Review Maternal Coronavirus Infections and Neonates Born to Mothers with SARS-CoV-2: A Systematic Review https://orcid.org/0000-0002-0824-1138do Amaral Waldemar Naves 1 https://orcid.org/0000-0003-0755-0753de Moraes Carolina Leão 1 https://orcid.org/0000-0002-0447-898XRodrigues Ana Paula dos Santos 1 https://orcid.org/0000-0002-1482-0718Noll Matias 2 https://orcid.org/0000-0001-7091-4850Arruda Jalsi Tacon 3 https://orcid.org/0000-0002-9902-8227Mendonça Carolina Rodrigues 1* 1 Programa de Pós-Graduação em Ciências da Saúde, Universidade Federal de Goiás, 74605-050 Goiânia, Brazil; waldemar@sbus.org.br (W.N.d.A.); carolina.leao.moraes2@gmail.com (C.L.d.M.); anapsr@gmail.com (A.P.d.S.R.) 2 Instituto Federal Goiano, Campus Ceres, 76300-000 Ceres, Brazil; matias.noll@ifgoiano.edu.br 3 Departamento de Medicina, Centro Universitário de Anápolis—UniEvangélica, 75083-515 Anápolis, Brazil; jalsitacon@gmail.com * Correspondence: carol_mendonca85@hotmail.com 24 11 2020 12 2020 8 4 51128 10 2020 16 11 2020 © 2020 by the authors.2020Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).The coronavirus disease 2019 (COVID-19) pandemic is continuously affecting the lives of all people. Understanding the impact of COVID-19 on pregnancy in terms of morbidity, mortality, and perinatal maternal and fetal outcomes is essential to propose strategies for prevention and infection control. Here, we conducted a systematic review to investigate pregnant women infected with COVID-19 in terms of signs and symptoms, type of delivery, comorbidities, maternal and neonatal outcomes, and the possibility of vertical transmission. A search on Embase and PubMed databases was performed on 31 October 2020. Observational studies and case reports on pregnant women infected with COVID-19 were included without language restrictions. The 70 selected studies included a total of 1457 pregnant women diagnosed with COVID-19 in the first, second, and third trimesters of pregnancy. The most common signs and symptoms were fever, cough, and nausea. The most frequent comorbidities were obesity, hypertensive disorders, and gestational diabetes. Among maternal and fetal outcomes, premature birth (n = 64), maternal death (n = 15), intrauterine fetal death or neonatal death (n = 16), cases of intrauterine fetal distress (n = 28), miscarriage (n = 7), decreased fetal movements (n = 19), and severe neonatal asphyxia (n = 5) were the most frequent. Thirty-nine newborns tested positive for SARS-CoV-2. Additionally, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was detected in the placenta (n = 13) and breast milk (n = 6). This review indicates that COVID-19 during pregnancy can result in maternal, fetal, and neonatal complications. In addition, SARS-CoV-2 viral exposure of neonates during pregnancy and delivery cannot be ruled out. Thus, we highlight the need for long-term follow-up of newborns from mothers diagnosed with COVID-19 to establish the full implications of SARS-CoV-2 infection in these children. pregnant womancoronavirusinfectious disease transmissionvertical transmissionobstetric managementSARS-CoV-2systematic review ==== Body 1. Introduction Coronavirus disease 2019 (COVID-19) is an infectious condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first reported in December 2019 after an outbreak of pneumonia of unknown etiology was identified in Wuhan, China [1,2]. Currently, the virus continues to spread to different regions of the world, including several countries in Europe and the United States, which reported the highest number of confirmed cases and deaths in March and April [2]. With continuous emergence of new data, there is an increasing understanding of the mechanisms of the disease [3]. Although studies about the effects of COVID-19 on pregnancy are expanding, there are still many unanswered questions [4,5]. Data regarding COVID-19 and its effects on both mother and fetus or newborn are still scarce, and the potential risk of vertical transmission is a major concern [6]. It is well established that pregnant women, in general, are vulnerable to infections; therefore, both pregnant women and newborns should be considered at risk for COVID-19 [6,7]. Thus, it is important to understand the impact of COVID-19 on pregnant women [6,8] in terms of morbidity, mortality, and perinatal maternal and fetal outcomes [7,9] to propose strategies for prevention and infection control [6]. Systematic reviews on the topic have already been published [10,11,12,13] and indicated that neonatal COVID-19 infection is low, and uncommonly symptomatic. As COVID-19 infection is growing in different cities around the world, new research is being published all the time. In this sense, a broad and current research on the maternal clinical characteristics of the COVID-19 infection and the neonatal results, during childbirth or postnatal (by environmental exposure), can provide important new information to guide clinical and preventive practice guidelines. Therefore, we aimed to investigate pregnant women infected with COVID-19 in terms of signs and symptoms, type of delivery, comorbidities, clinical outcomes (maternal and neonatal), and possibility of vertical transmission (via placenta or hematogenous route, birth canal, and lactation) through a systematic review. We believe that these findings will make a significant contribution to the current clinical and preventive practice guidelines worldwide. 2. Materials and Methods A systematic review on pregnancy and COVID-19 was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [14] guideline. Our study was conducted in six stages: (1) Formulation of the study question, (2) elaboration of inclusion and exclusion criteria, (3) definition of the information to be extracted from the identified and selected articles, (4) analysis, (5) interpretation of results, and (6) presentation of the review [15]. The protocol was registered with PROSPERO (CRD42020220263). 2.1. Information Sources and Search Strategy An electronic search was performed in Embase and PubMed databases for articles published until 31 October 2020. The reference lists of selected articles and information available on Google Scholar were also searched. The following keywords were used for the searches: Pregnancy, pregnant woman, pregnant women, COVID-19, SARS-CoV-2, and vertical transmission. Operator fields were filled out with AND/OR. We used the following terms to search in PubMed: ((Pregnancy) OR (pregnant woman) OR (pregnant women)) AND ((COVID-19) OR (SARS-CoV-2) OR (coronavirus pregnancy) AND (vertical transmission)). 2.2. Eligibility Criteria The inclusion criteria were as follows: (1) Outpatient or population-based observational studies (prospective or retrospective) or case reports and pre-print articles (2) in any language, (3) published between December 2019 and October 2020; (4) studies with pregnant women with laboratory diagnosis for COVID-19; and (5) pregnant women in any gestational trimester. Letters to the editor, opinions, comments, correspondence articles reporting previously published data, reviews, guidelines, and duplicate studies (i.e., found in more than one database) were excluded. 2.3. Data Extraction and Quality Assessment Titles and abstracts were used to screen for potentially eligible studies. The identified studies were then read in full and critically evaluated by three members of the research team (C.R.M., C.L.M., and J.T.A.) (Figure 1) based on their knowledge on pregnancy and COVID-19. Doubts and/or disagreements about the articles were discussed by the research team to make a consensus decision. The data extracted from the studies were as follows: (1) Signs and symptoms of the mother and fetus, (2) gestational age and pregnancy results (maternal or fetal death), (3) type of delivery (natural, emergency or elective cesarean section, abortion, or complications), and (4) possibility of SARS-CoV-2 vertical transmission. The quality of the studies was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) [16,17]. The quality of the evidence from the studies was classified into four categories: High, moderate, low, or very low [16,17]. 3. Results A flow diagram based on the PRISMA guideline was created to represent the different stages of article selection (Figure 1). 3.1. Study Selection From the 1720 studies retrieved, 1708 were identified in Embase and PubMed while 12 were taken from other sources. After exclusion of duplicate studies, a total of 1035 titles and abstracts were collected. Among these, 218 manuscripts were retrieved for full reading by the three authors (C.R.M., C.L.M., and J.T.A.) independently. A total of 70 studies met the inclusion criteria [5,7,9,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85]. The main findings of the selected studies are shown in Table 1. The distribution of studies in terms of quality of evidence based on GRADE are as follows: High quality (n = 1) [41], moderate quality (n = 11) [9,21,22,33,48,49,50,52,55,63,68], low quality (n = 26) [5,9,23,24,25,26,28,29,36,40,43,46,47,51,54,56,60,61,62,64,65,66,67,69,70,73], and very low quality (n = 32) [7,18,20,27,30,31,32,34,35,37,38,39,42,44,45,53,57,58,59,66,71,72,74,75,77,78,79,80,81,83,84,85]. The studies that were classified as “low-quality” and “very low-quality” are case reports or small series of cases which also characterizes a high risk of bias. 3.2. Synthesis of Results Of the 70 studies included, 34 were carried out in China [5,9,25,26,27,28,30,31,32,42,43,44,45,46,47,53,54,57,58,59,60,61,62,63,64,65,66,67,68,69,70,73,78], 10 in the United States [21,22,23,37,48,49,52,75,79,85], eight in Italy [24,33,51,55,81,82,83,84], three in Iran [36,39,76], one in Korea [7], one in Turkey [38], one in Peru [18], one in Switzerland [20], two in France [56,74], three in Spain [50,77,80], one in Australia [71], one in Spain [72], one in the Netherlands and Ireland [34], one in Canada [40], one in the United Kingdom [41], and one in Sweden [35]. A total of 1457 pregnant women diagnosed with COVID-19 and 1042 newborns from infected mothers were included. Maternal SARS-CoV-2 infection was diagnosed by reverse transcriptase–polymerase chain reaction (RT-PCR or PCR) of nasopharyngeal swabs and sputum samples [9]. 3.3. Signs and Symptoms Among infected pregnant women, 116 (7.9%) were asymptomatic at the beginning of medical care. Of the symptomatic pregnant women, the most frequent symptoms were fever (>37.3 °C) (n = 695, 47.7%), cough (n = 647, 44.4%), and nausea (n = 148, 10.2%). Less common symptoms included dyspnea (n = 87, 6.5%), fatigue (n = 58, 4.3%), myalgia (n = 42, 2.9%), and diarrhea (n = 14, 0.9%). In the immediate postpartum period, the most frequent symptom was fever (37.8–39.33 °C). 3.4. Gestational Age Twenty-one (1.4%) of the pregnant women were in the first trimester, 97 (6.6%) in the second trimester, and 1339 (91.9%) in the third trimester of pregnancy. 3.5. Type of Delivery In terms of the type of delivery, 597 (57.3%) underwent elective cesarean section, 36 (3.4%) received emergency cesarean sections, and 364 (34.9%) went through spontaneous vaginal delivery. 3.6. Comorbidity and Pregnancy Complications The most reported maternal comorbidities were obesity (n = 191, 13.1%), hypertensive disorders (n = 117, 8.0%), diabetes (n = 49, 3.3%), asthma (n = 44, 3.0%), and preeclampsia (n = 15, 1.0%). Pregnancy complications included gestational diabetes (n = 91, 6.2%) and gestational hypertension (n = 12, 0.8%). Comorbidities and complications in pregnant women with COVID-19 are described in Table 2. 3.7. Maternal Outcomes Among pregnant women diagnosed with COVID-19, 68 (4.6%) were admitted in intensive care units (ICU) [21,22,23,33,36,55,56,67,85]. There were 15 (1.0%) cases of maternal death [21,36,39,41], mostly from United Kingdom (n = 5) [41] and Iran (n = 7) [36]. Hantoushzadeh et al. [36] reported that pregnant women with SARS-CoV-2 infection in the second or third trimester of pregnancy can suffer cardiopulmonary complications and die. 3.8. Neonatal and Fetal Outcomes Among neonates born to infected mothers, 187 (17.9%) required admission to neonatal ICUs [18,26,33,41,50,55,56,63,65,66,85]. There were 16 (1.5%) total cases of neonatal death and fetal intrauterine death [20,36,39,41,42,48,49,63,70]. Karami et al. reported a case of an infected pregnant woman who vaginally delivered a cyanotic fetus in the third trimester [39]. In the study by Zhu et al. [67], a newborn delivered at 34 + 5 weeks of gestation from a 30-year-old mother with COVID-19 experienced refractory shock, gastric bleeding, multiple organ failure, and disseminated intravascular coagulation. There were four total cases of fetal demise: One at 17 weeks [49] and three at the third trimester of pregnancy [42,48,63]. Lookken et al. [48] reported one case of stillbirth at 38.7 weeks in which the qualitative PCR tests of placental and fetal tissue were negative for SARS-CoV-2 and cytomegalovirus. However, the delay between fetal death and sample extraction for PCR analysis may have led to inaccurate results. In the study by Li et al. [42], biochemical examination of umbilical cord blood at birth revealed a marked increase in myocardial enzymes, suggesting severe damage of the fetal myocardium. Considering severe hypoxia, the possibility of immunologic damage cannot be ruled out. This may have led to difficulties in resuscitation and eventually neonatal death. Maternal hypoxia and unstable circulation secondary to COVID-19 can endanger the fetus and cause intrauterine fetal death [42]. Among the seven total cases (0.7 %) of miscarriage [20,24,41,56], the distribution by type are as follows: Spontaneous miscarriage (n = 1) [24], threatened miscarriage (n = 1) [29], medical miscarriage (n = 4) [54], and induced miscarriage (n = 1) [29]. Among various studies, there were 64 (6.1%) cases of premature birth [25,36,54,61,63,64,69,70,73,75,76,77,82,85], 10 (0.9%) patients with complications in pregnancy [73], and 28 (2.7%) cases of intrauterine fetal distress [25,47,48,53,60,63,68,69,70,73,84]. Decreased fetal movements were reported for 19 (1.8%) fetuses [21,30,36,37,38,49,57,58,68,69]. There were five (0.5%) cases of severe neonatal asphyxia [63,64,69] and four (0.3%) cases of low birth weight (<2500 g) in the third pregnancy trimester [25,63]. Abnormal fetal heart monitoring [29], fetal tachycardia [28,34], and placental detachment [48] were also reported. Other outcomes include premature rupture of membranes (n = 26, 2.5%) [36,50,62,69,86], abnormal amniotic fluid (n = 3, 0.3%) [69,70], and abnormal umbilical cord in the third pregnancy trimester (n = 6, 0.6%) [64,70]. 3.9. Newborns and Placental and Breast Milk Samples Tested Positive for SARS-COV-2 Of the 70 studies analyzed, 21 studies included a total of 39 (3.7%) newborns who tested positive for SARS-CoV-2 [18,24,33,36,40,41,50,51,55,58,66,68,74,75,76,82,83]. In only five studies (23.8%), newborns were tested within the first 12 h of birth [33,41,50,74,76]. Two studies have presented neonates with symptoms; however, tests for SARS-CoV-2 were negative [32,35]. SARS-CoV-2 RNA was detected in 13 placenta samples [20,51,52,74,79,81,82,83,85] and six breast milk samples of infected pregnant women [61,82,84]. There was also a positive test for SARS-CoV-2 RT-PCR in umbilical cord and vagina samples [82] (Table 3). In addition, one newborn received an inconclusive result but was otherwise asymptomatic [22]. Twelve newborns presented IgG positive in umbilical cord plasma [82] and two neonates born to a mother with COVID-19 had elevated antibody levels (IgM) 2 h after birth [31,82]. 3.10. Newborns Tested Negative for SARS-COV-2 and Vertical Transmission A total of 959 newborns were asymptomatic at birth and had negative results for SARS-CoV-2. The distribution of oropharyngeal swab collection time for RT-PCR among studies in which newborns were negative are as follows: At birth (n = 51) [21,24,31,32,33,34,35,36,38,44,47,48,49,51,54,56,58,61,70,71,73,77,78,80], 72 h after birth (n = 1) [70], fifth day (n = 1) [69], seventh and ninth days (n = 1) [70], and fourth to fourteenth days (n = 1) [46]. In addition to oropharyngeal swabs, other samples for testing included placental tissue [7,26,27,29,30,32,38,44,47,53,58,59,62,78], fetal membrane [27], umbilical cord blood [5,7,20,29,32,38,44,45,53,58,59,65,78], breast milk [25,29,31,32,35,38,44,45,47,53,57,58,80], amniotic fluid [7,20,25,29,44,45,53,59,62,65,78], serum [32,53], bronchoalveolar lavage fluid [53], vaginal secretions [20,31,32,53], axillary swab [20], mouth swab [20], neonatal gastric fluid [78], meconium [20], urine [44,45,53], rectal swab samples [24,56], feces [44,45,57], and anal swab [53,61,78]. In addition to RT-PCR, other tests such as IgM and IgG antibody [31,64], cytokine [31], and blood biochemistry tests [31] were also used. The results of all the various tests using a myriad of samples were negative. In one study, the presence of SARS-CoV-2 was investigated in vaginal discharge and amniotic fluid in four pregnant women with mild acute symptoms of COVID-19 who underwent amniocentesis during the second trimester of pregnancy [72]. In addition, in another study, a case of vaginal delivery without complications was described in a mother with COVID-19 [47]. The test for neonatal COVID-19 24 h after delivery was still negative despite the fact that the infant was breastfed and not separated from the mother [71]. 4. Discussion This systematic review gathered evidence available on pregnancy and SARS-CoV-2 infection from the international literature to investigate signs and symptoms, type of delivery, comorbidities, clinical outcomes (maternal and neonatal), and vertical transmission risk of COVID-19. This study included a significant number of newborns and pregnant women diagnosed with COVID-19 in the first, second, and third trimesters of pregnancy. Although most studies which were included were case reports or case series that have low levels of evidence quality, these are still important in the current context due to the need for information to support public health policies. In terms of signs and symptoms of COVID-19, fever above 37.0 °C was the most frequent symptom reported by pregnant women, followed by cough and nausea in the prenatal period. In the postpartum period, subjects were reported to experience fever (37.8–39.33 °C) and a general worsening of the condition, especially in those who were initially asymptomatic. Among symptomatic pregnant women, 4.99% were admitted in the ICU. The results in our study are consistent with those of studies in the general population, where fever and coughing were the most reported symptoms [87]. Obesity and hypertensive disorders were the most reported comorbidities in pregnant women with COVID-19. It is noted that the majority of the pregnant women did not have serious complications, with a low occurrence of maternal death (1.0%) and premature rupture of the membrane (2.5%). However, pregnancy complications, including gestational diabetes and gestational hypertension, were reported. Many pregnant women presented with worsening of the general condition that required an induced delivery or emergency cesarean section. However, we found that the maternal risk in pregnant women diagnosed with COVID-19 was relatively low. In contrast, 17.9% of newborns were admitted in the neonatal ICU. Fetal and neonatal complications including premature delivery (6.1%), fetal distress (2.7%), decreased fetal movements (1.8%), and fetal and neonatal death (1.5%) were identified. There were also cases of miscarriage and severe neonatal asphyxia. Therefore, we hypothesize that there is a greater risk of fetal and neonatal complications in the first and second trimesters of pregnancy. This systematic review included cases where SARS-CoV-2 RNA was detected in the placenta (n = 13), breast milk (n = 6), and neonates (n = 39). It is important to note that only five studies confirmed a diagnosis within the first 12 h of birth. In other studies, SARS-CoV-2 was detected 12 h after birth, hinting at the possibility of late-onset neonatal infection. Nevertheless, we highlight that 92% of newborns from mothers infected with COVID-19 did not acquire the infection during birth. Although there is a theoretical risk of vertical transmission, it seems to be low and, so far, remains poorly understood. It has been reported that the placental barrier does not allow for the passage of SARS-CoV-2 [88]. However, there is evidence of histopathologic placental changes in women infected with COVID-19, showing poor maternal vascular perfusion and inflammation [89]. It is not clear whether this can disrupt the maternal–placental interface to allow the transplacental transmission of SARS-CoV-2 [89]. Furthermore, its role in the occurrence of premature births and other fetal complications remains unknown. Thus, more robust studies, preferably longitudinal studies, involving a large sample size with long-term follow-up are crucial to establish the full implications of COVID-19 on pregnancy and early development. It is unclear whether maternal and newborn COVID-19 infection will cause any sequelae in childhood. Nevertheless, it is essential to formulate guidelines for the management of pregnant women infected with SARS-CoV-2 as a way to minimize viral exposure and transmission [7]. These protocols also play important roles in protecting the medical team and providing a suitable hospital environment (e.g., respiratory precautions, use of personal protective equipment, and negative pressure rooms) [90]. The Lancet Infectious Diseases has published guidelines on the management of pregnant women exposed to COVID-19. For asymptomatic cases, home isolation for 14 days is recommended. In symptomatic cases, key recommendations include prioritization of vaginal delivery when possible, late fixation of the umbilical cord, without early cleaning of the newborn, and isolated neonatal surveillance. In both cases, mother–child separation and breastfeeding are discussed individually by an interdisciplinary team [19]. In addition, a recent guideline published in June recommends that for cases where separation is not applicable, other measures to reduce risk of infection (e.g., physical barriers and face mask) must be adopted. For those who choose to breastfeed, mothers must wear face masks and practice good hygiene (hand and breast) before each feeding. Newborns from mothers with confirmed or suspected COVID-19 at the time of the delivery should be tested 24 h after birth. If negative, another test at approximately 48 h must be done if testing capacity is available [91]. 4.1. Strengths and Limitations This review was completed after an extensive bibliographic search using two databases, reference lists, and Google Scholar. We included a large number of pregnant women diagnosed with COVID-19 from 16 countries and data on the first, second, and third trimesters of pregnancy. However, our study has some limitations: First, our findings are mostly limited to case reports and retrospective studies with a small number of cases analyzed. Second, there was a lack of methodological criteria in the conduction of many included studies, which can contribute to erroneous results. However, it is important to highlight that we have gathered all the evidence available in the literature to date and that this information is important to guide health and management policies for pregnant women affected by COVID-19 in the first, second, and third trimesters of pregnancy. In addition, the justification for conducting our study is the need to quickly assess and discuss the evidence that has been generated. Finally, some relevant publications may have been released during the submission or publication process of this paper. 4.2. Future Recommendations With the worsening of the COVID-19 global situation, new well-designed research is needed to clarify the risk of vertical transmission (via placenta or hematogenous routes, birth canal, and lactation) of SARS-CoV-2. In addition, further studies are necessary to investigate potential therapeutic interventions that prevent maternal and neonatal morbidity and possible sequelae resulting from COVID-19 infection. In addition, it is important that future studies assess complications arising from COVID-19 in pregnant women in the first and second trimester. These studies are important to improve clinical and preventive strategies for managing COVID-19 in pregnant women and their newborns. 5. Conclusions This review revealed that pregnant women with COVID-19 usually present with fever, cough, and nausea. Among various comorbidities, obesity and hypertensive disorders are the most common. It is important to highlight the prevalence of premature birth, maternal death, premature rupture of the membrane, intrauterine fetal death, neonatal death, miscarriage, decreased fetal movements, and severe neonatal asphyxia among cases of infected mothers. Although we found only 27 cases of newborns infected with COVID-19, viral exposure of SARS-CoV-2 during pregnancy and intrapartum period cannot be ruled out and should be further investigated in future studies. Thus, it is important to follow-up all newborns from mothers diagnosed with COVID-19. Acknowledgments Instituto Federal Goiano and Universidade Federal de Goiás for partial supporting. Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Author Contributions Conceptualization, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; methodology, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; formal analysis, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; investigation, C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; resources, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; data curation, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; writing—original draft preparation, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; writing—review and editing, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; visualization, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; supervision, W.N.d.A., C.L.d.M., A.P.d.S.R., M.N., J.T.A. and C.R.M.; funding acquisition, W.N.d.A. and M.N. All authors have read and agreed to the published version of the manuscript. Funding This work was carried out with its own financing. Conflicts of Interest The authors declare no conflict of interest. Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. healthcare-08-00511-t001_Table 1Table 1 Data on signs and symptoms, gestational age, type of delivery, comorbidity, and vertical transmission of coronavirus disease 2019 (COVID-19) in pregnant women. First Author, Year, and Country Study Size and Age Study Design Signs and Symptoms Gestational Age Type of Delivery and Maternal or Fetal Complications GRADE * Before Delivery Postpartum Algarroba, et al., 2020 [85] EUA n = 1 Age: 40 years Case report Worsening shortness of breath, cough, and hypoxia NR Third trimester (28 weeks gestational age) Cesarean delivery (n = 1) ●○○○ Alzamora et al., 2020 [18] Peru n = 1 Age: 41 years Case report General malaise, fatigue, and low-grade fever NR Third trimester (33 weeks gestational age) Emergency cesarean section (n = 1) ●○○○ Baud et al., 2020 [20] Switzerland n = 1 Age: 28 years Case report Fever (39.2 °C), myalgia, fatigue, mild pain with swallowing, diarrhea, and dry cough for 2 days NR Second trimester (19 weeks gestational age) Vaginal deliveries (after 10 h of labor) (n = 1) ●○○○ Blitz et al., 2020 [21] USA n = 13 Mean maternal age 33.8 ± 5.2 Case series Fever, subjective or measured (n = 12) Cough (n = 13) Dyspnea (n = 10) Myalgia (n = 6) Fatigue or malaise (n = 3) NR Third trimester (mean weeks gestational age 33.3 ± 5.3) Cesarean for acute respiratory decompensation (n = 5) Cesarean for obstetrical indication (n = 1) Vaginal delivery (n = 1) ●●●○ Breslin et al., 2020 [22] USA n = 43 Mean maternal age 29.7 ± 6.0 Case series, retrospective Symptomatic gestates (n = 29) Asymptomatic pregnant women (n = 14) Fever ≥37.5 °C (100.0 °F) (n = 14) Cough (n = 19) Myalgia or fatigue (n = 11) Dyspnea (n = 7) Headache (n = 8) Chest pain (n = 5) Worse fever or increased breathing work Third trimester (≥37 weeks gestational age) Cesarean delivery (n = 8) Vaginal deliveries (n = 18) ●●●○ Breslin et al., 2020 [23] USA n = 7 Age: 27 to 39 years Case series Fever ≥37.0 °C (100.0 °F) (n = 2) Cough (n = 3) Myalgias (n = 3) Chest pain (n = 2) Headache (n = 2) Fever Severe hypertension Cough Severe bronchospasm and disproportionate reactive lung disease Third trimester (≥37 weeks gestational age) Emergency cesarean section (n = 7) ●●○○ Buonsenso et al., 2020 [24] Italy n = 7 Age: 27 to 39 years Observational study NR Asymptomatic (n = 1) NR Second trimester (≥20 weeks gestational age) Cesarean section (n = 2)—third trimester ●●○○ Chen et al., 2020 [28] China n = 5 Age: 25 to 31 years Descriptive study Cough Sputum Coryza Asymptomatic (n = 3) Low fever (37.5–38.5 °C) (n = 5) Third trimester (39–40 weeks) Emergency cesarean section (n = 1) (preeclampsia—fetal tachycardia) Elective cesarean section (n = 1) (gestational diabetes) Vaginal delivery (n = 3) ●●○○ Chen et al., 2020 [25] China n = 9 Age: 26 to 40 years Descriptive, retrospective study Low fever without chills (n = 7) Myalgia (n = 3) Malaise (n = 2) Cough (n = 4) Dyspnea (n = 1) Sore throat (n = 2) Diarrhea (n = 1) Fever (variation of 37.8–39.33 °C) (n = 6) Third trimester (≥36 weeks gestational age) Cesarean (n = 9) ●●○○ Chen et al., 2020 [27] China n = 3 Age: 23 to 32 years Descriptive, retrospective study Fever and chest tightness (n = 1) Fever (n = 3) Third trimester (≥35 weeks gestational age) Emergency cesarean section (n = 3) ●○○○ Chen et al., 2020 [26] China n = 17 Mean maternal age 29.7 years Descriptive, retrospective study Mild fever without chills (≤39 °C) (n = 4) Cough (n = 4) Fatigue (n = 1) Chest distress (n = 2) Dyspnea (n = 1) Diarrhea (n = 1) NR Third trimester (≥35 weeks gestational age) Elective cesarean delivery (n = 14) Emergency cesarean delivery (n = 3) ●●○○ Chen et al., 2020 [30] China n = 4 Age: 23 to 34 years Case report Fever (n = 3) Cough (n = 2) Fatigue (n = 2) Headache (n = 2) Dyspnea (n = 2) Anemia and dyspnea Third trimester (≥37 weeks gestational age) Cesarean section (n = 3) Vaginal delivery (n = 1) ●○○○ Chen et al., 2020 [29] China n = 3 Age: 23 to 34 years Case report Cough (n = 3) Fever (n = 3) Fatigue (n = 3) Diarrhea, nausea, and vomiting NR First trimester (6 weeks) Second trimester (25 weeks) Third trimester (35 weeks) Cesarean section delivery (n = 1) ●●○○ Costa et al., 2020 [84] Italy n = 2 Age: 38 years and 42 years Case report Fever, shortness of breath, and diarrhea (n = 1) Cough (n = 1) NR Third trimester (n = 2) (≥34 weeks gestational age) Caesarean section (n = 2) ●○○○ Dong et al., 2020 [31] China n = 1 Age: 29 years Case report Fever, nasal congestion Liver injury NR Third trimester (34 weeks) Cesarean section delivery (n = 1) ●○○○ Elósegui et al., 2020 [72] Spain n = 4 Age: 27 to 40 years Case series Mild clinical symptoms NR Second trimester SARS-CoV-2 in vaginal discharge and amniotic fluid in Caucasian pregnant women affected by mild acute symptoms of COVID-19 ●○○○ Facchetti et al., 2020 [83] Italy n = 1 Age: 29 Case report Fever and idiopathic thrombocytopenia NR Third trimester (37 weeks gestational age) Vaginal delivery was induced (n = 1) ●○○○ Fan et al., 2020 [32] China n = 2 Age: 34 years and 29 years Case report Nasal congestion (n = 2) Fever (37. 3–38.5 °C) (n = 2) Skin rash (n = 1) Chill (n = 1) Sore throat (n = 1) NR Third trimester (37 weeks gestational age) (36 weeks gestational age) Cesarean section delivery (n = 2) ●○○○ Ferrazzi et al., 2020 [33] Italy n = 42 Mean maternal age 32.9 Retrospective multicenter study Fever (n = 20), cough (n = 7), myalgia/malaise (n = 7), dyspnea (n = 8) NR Third trimester (±30 weeks gestational age) Elective cesarean (n = 18) Vaginal delivery (n = 24) ●●●○ Fenizia et al., 2020 [82] Italy n = 31 Median age: 30 Case report NR Admission to ICU and invasive ventilation (n = 1) Third trimester (weeks median: 39) Vaginal delivery (n = 25) Caesarean section (n = 6) ●●○○ Ferraiolo et al., 2020 [81] Italy n = 1 Age: 30 Case report Asymptomatic Asymptomatic Third trimester (38 weeks gestational age) Urgent cesarean section ●○○○ Fontanella et al., 2020 [34] the Netherlands and Ireland n = 2 Age: 39 years and 29 years Case report Fever ≥37.3 °C (n = 2) (1) Cough and increasing dyspnea, thoracic pain with deep breathing (2) Productive cough, sore throat, and diarrhea NR Third trimester (31 weeks gestational age) (40 weeks gestational age) Cesarean (n = 2) ●○○○ Gabriel et al., 2020 [80] Spain n = 7 Median age: 33–43 Observational prospective Asymptomatic (n = 6) Fever, malaise, myalgia, headache (n = 1) NR Third trimester (≥38 weeks gestational age) Vaginal delivery (n = 6) Cesarean section (n = 1) ●○○○ Gidlöf et al., 2020 [35] Sweden n = 1 Age: 34 years Case report Hoarseness Increasing malaise Severe headache and photophobia Oxygen saturation dropped to 87% Pulmonary edema/embolism Third trimester (36 weeks gestational age) Emergency cesarean—dichorionic twin pregnancy (n = 2) ●○○○ Hantoushzadeh et al., 2020 [36] Iran n = 9 Age: 25 to 49 years Case series Fever (n = 9) Cough (n = 9) Dyspnea (n = 6) Myalgia (n = 4) NR Second trimester (n = 2) Third trimester (n = 7) Cesarean delivery (n = 6) Vaginal delivery (n = 1) ●●○○ Hosier et al., 2020 [79] USA n = 1 Age: 35 Case report Fever, malaise, nonproductive cough, diffuse myalgias, anorexia, nausea, and diarrhea NR Second trimester (22 weeks gestational age) Urgent cesarean section ●○○○ Iqbal et al., 2020 [37] USA n = 1 Age: 34 years Case report Fever, chills, dry cough, and myalgia Fever 38.5 °C Third trimester (39 weeks of gestation) Spontaneous vaginal delivery (n = 1) ●○○○ Kalafat et al., 2020 [38] Turkey n = 1 Age: 32 years Case report Nausea Dyspnea Swollen left leg NR Third trimester (35 weeks gestational age) Cesarean (n = 1) ●○○○ Karami et al., 2020 [39] Iran n = 1 Age: 27 years Case report Fever, cough, and myalgia for 3 days NR Third trimester (30 and 3/7 weeks gestation) Vaginal delivery (n = 1) ●○○○ Khan et al., 2020 [5] China n = 3 Age: 27 to 33 years Case report Cough (n = 3) Fever (≥37.3 °C) (n = 2) Chest tightness (n = 1) NR Third trimester (≥34 weeks of gestation) Vaginal delivery (n = 3) ●●○○ Kirtsman et al., 2020 [40] Canada n = 1 Age: 40 years Case report Cough Pyrexia Tachycardic (110–121 beats/min) Fever (39 °C) NR Third trimester (35 + 3 weeks gestation) Cesarean delivery (n = 1) ●●○○ Knight et al., 2020 [41] UK n = 427 Cohort study Fever (n = 280) Cough (n = 240) Breathlessness (n = 160) Tiredness or lethargy (n = 70) Headache (n = 60) NR Second trimester (≤26 weeks) (n = 4) Third trimester (>27 weeks) (n = 96) Caesarean, maternal indication due to SARS-CoV-2 (n = 42) Caesarean, other indication (n = 114) Operative vaginal (n = 28) Unassisted vaginal (n = 78) ●●●● Lee et al., 2020 [7] Korea n = 1 Age: 35 years Case report Fever (>38 °C), mild sore throat and cough NR Third trimester (37 weeks gestational age) Cesarean delivery (n = 1) ●○○○ Li et al., 2020 [43] China n = 16 Age: 26 to 37 years Case-control study Fever (n = 4) Cough (n = 4) Fever (n = 8) Third trimester (Mean weeks gestational age = 38 ± 0.2) Total: 17 babies Vaginal delivery (n = 2) Cesarean section (n = 14) Twin pregnancy ●●○○ Li et al., 2020 [44] China n = 1 Age: 30 years Case report Fever (37.2 °C), chills, or shortness of breath NR Third trimester (35 weeks gestational age) Emergency cesarean section (n = 1) ●○○○ Li et al., 2020 [42] China n = 1 Age: 31 years Case report Fever and dyspnea to acute respiratory distress syndrome and septic shock NR Third trimester (35 + 2 weeks gestational age) Cesarean delivery (n = 1) ●○○○ Liao et al., 2020 [45] China n = 1 Age: 25 years Clinical case reported in a letter to the editor Fatigue and mild dry cough for 3 days Fever (38.3 °C) NR Third trimester (35 weeks gestational age) Emergency cesarean section (n = 1) ●○○○ Liu et al., 2020 [9] China n = 16 Age: 22–42 years Retrospective study Fever (n = 7) Cough (n = 6) Short of breath (n = 2) Fatigue (n = 3) Fever (n = 5) Third trimester (>22 weeks gestational age) Cesarean section (n = 10) ●●●○ Liu et al., 2020 [46] China n = 15 Age: 23 to 40 years Case report Fever (n = 13) Cough (n = 9) Sore throat (n = 1) Dyspnea (n = 1) Myalgia (n = 3) Fatigue (n = 4) Diarrhea (n = 1) Asymptomatic (n = 2) Fever (n = 1) First and third trimesters (≥27 weeks gestational age) (12 to 38 weeks) Cesarean section (n = 10) Vaginal delivery (n = 1) ●●○○ Liu et al., 2020 [47] China n = 3 Age: 30 to 34 years Case series study Fever (37.8 °C) (n = 2) Cough (n = 2) NR Third trimester (>38 weeks gestational age) Cesarean section (n = 2) Natural childbirth (n = 1) ●●○○ Lv et al., 2020 [78] China n = 1 Age: 28 Case report Fever and cough NR Third trimester (31 weeks gestational age) Cesarean section ●○○○ Lokken et al., 2020 [48] USA n = 46 Age: 26 to 34 years Retrospective study Symptomatic (n = 43) Cough (n = 30) Fever or chill (n = 22) Nasal congestion (n = 21) Shortness of breath/dyspnea (n = 19) (44.2%) Asymptomatic (n = 3) NR Second or third trimester Vaginal (n = 5) Cesarean (n = 3) Preterm birth at 33 weeks (n = 1) ●●●○ London et al., 2020 [49] USA n = 68 Age: ≥30 years Retrospective cohort study Fever (n = 46) Cough (n = 46) Shortness of breath (n = 46) Sore throat (n = 46) Nausea (n = 46) Vomiting (n = 46) Asymptomatic (n = 22) NR First trimester (17 weeks gestational age) (n = 1) Second trimester (25 and 26 weeks) (n = 2) Third trimester (n = 65) Cesarean delivery (n = 22) ●●●○ Lowe et al., 2020 [71] Australia n = 1 Age: 31 years Case report Initially remained asymptomatic Fever NR Third trimester (40 weeks gestational age) Vaginal delivery ●○○○ Martínez-Perez et al., 2020 [50] Spain n = 82 Age: 33 years Cohort Symptomatic gestates (n = 60) Asymptomatic pregnant women (n = 22) NR Third trimester (≥29 weeks gestational age) Delivered vaginally (n = 49) Cesarean delivery (n = 33) ●●●○ Patanè et al., 2020 [51] Italy n = 22 Age: 33 years Retrospective cohort study Fever 38 °C (n = 2) Dry cough (n = 2) NR Third trimester (≥37.6 weeks gestational age) Vaginal delivery (n = 1) Cesarean delivery (n = 1) ●●○○ Penfield et al., 2020 [52] USA n = 32 Age: 22 to 40 years Retrospective cohort study NR NR Second and Third trimester (≥26 weeks) Cesarean delivery (n = 4) Normal spontaneous vaginal delivery (n = 7) ●●●○ Peng et al., 2020 [53] China n = 1 Age: 22 to 40 years Case report Fever, fatigue, shortness of breath NR Third trimester (35.2 weeks gestational age) Cesarean (n = 1) ●○○○ Pereira et al., 2020 [77] Spain n = 60 Median age: 34 years Descriptive Fever and cough Admission to ICU (n = 1) (with HELLP syndrome) Third trimester (median: 32 weeks) During the study period, 23 women delivered: Cesarean section (n = 5) Vaginal (n = 18) ●○○○ Qiancheng et al., 2020 [54] China n = 28 Mean maternal age 30 26.75–32 Single-center, retrospective study Cough (n = 7) Fever (n = 5) Abdominal pain (n = 5) Dyspnea (n = 2) Malaise (n = 1) NR First trimester (n = 3) Second trimester (n = 1) Third trimester (n = 24) Cesarean section (n = 17) Vaginal delivery (n = 5) ●●○○ Savasi et al., 2020 [55] Italy n = 91 Age: 15 to 48 years Retrospective cohort study Fever (n = 54) Cough (n = 62) Dyspnea (n = 27) Symptomatic (n = 10) First trimester (n = 4) Second trimester (n = 13) Third trimester (n = 50) Cesarean (n = 31) Vaginal (n = 36) ●●●○ Schwartz et al., 2020 [76] Iran n = 9 Age: 28 Retrospective cohort study NR NR Third trimester (>28 weeks gestational age) Cesarean section (n = 8) Spontaneous vaginal delivery (n = 1) ●●○○ Sentilhes et al., 2020 [56] France n = 38 Age: 19 to 42 years Retrospective single-center study Fatigue (n = 38) Cough (n = 25) Anosmia or ageusia (n = 18) Fever (n = 10) NR Third trimester (mean weeks gestational age 29.3 ± 8.5) Cesarean (n = 6) Vaginal (n = 10) ●●○○ Sisman et al., 2020 [75] USA n = 1 Age: 37 Case report Fever NR Third trimester (34 weeks gestational age) Vaginal delivery (n = 1) ●○○○ Siying et al., 2020 [57] China n = 1 Age: 33 Case report Dry cough 1 day before admission, without sputum, sore throat, fatigue Dry cough Third trimester (37 weeks gestational age) Emergency caesarean section (n = 1) ●○○○ Vivanti et al., 2020 [74] France n = 1 Age: 23 Case report Fever (38.6 °C), severe cough, and abundant expectoration NR Third trimester (35 + 2 weeks of gestation) Cesarean delivery (n = 1) ●○○○ Wang et al., 2020 [59] China n = 1 Age: 28 Case report Fever NR Third trimester (30 weeks pregnant) Emergency cesarean (n = 1) ●○○○ Wang et al., 2020 [58] China n = 1 Age: 34 Case report Fever (37.8 ℃) NR Third quarter (40 weeks gestational age) Emergency cesarean (n = 1) ●○○○ Wu et al., 2020 [60] China n = 23 Age: 21–37 years Case report Cough (n = 6), Fever (n = 4) Nasal congestion (n = 1) Clinically asymptomatic (n = 15) NR First trimester (n = 3) (≤12 weeks) Third trimester (n = 20) (≥28 weeks gestational age) Cesarean section (n = 18) Vaginal delivery (n = 2) ●●○○ Wu et al., 2020 [61] China n = 13 Age: 26–40 years Descriptive study, retrospective Fever (n = 8) Cough (n = 5) Dyspnea (n = 1) Myalgia (n = 1) Diarrhea (n = 1) NR First trimester (n = 5) Second trimester (n = 3) Third trimester (n = 5) Caesarean section (n = 4) Natural delivery (n = 1) ●●○○ Xiong et al., 2020 [62] China n = 1 Age: 25 years Case report Fever (38 °C) Dry cough Shivering NR Third trimester (33 weeks gestational age) Vaginal delivery six hours after (n = 1) ●●○○ Yan et al., 2020 [63] China n = 116 Mean maternal age 30.8 ± 3.8 Descriptive study, retrospective Fever (n = 59) Cough (n = 33) Clinically asymptomatic (n = 27) NR Third trimester (≥ 38 weeks gestational age) Cesarean delivery (n = 85) Vaginal delivery (n = 14) ●●●○ Yang et al., 2020 [64] China n = 26 Age: 21 to 40 years Retrospective study Fever (13 cases), cough (10 cases), vomiting (1 case) NR Third trimester (≥30 weeks gestational age) Cesarean section (n = 20); Vaginal (n = 6 cases) ●●○○ Yang P et al., 2020 [65] China n = 7 Age: 21 to 40 years Case report Fever (n = 5) Cough (n = 1) Abdominal pain (n = 1) Fever Third trimester (≥36 weeks gestational age) Cesarean delivery (n = 7) ●●○○ Yu et al., 2020 [66] China n = 7 Age: 29 to 34 years Descriptive study, retrospective Fever (n = 6) Cough (n = 1) Shortness of breath (n = 1) Diarrhea (n = 1) NR Third trimester (≥37 weeks gestational age) Cesarean delivery (n = 7) ●●○○ Yu et al., 2020 [67] China n = 1 Age: 35 Descriptive study, retrospective Low fever and dry cough Dyspnea and cyanosis Third trimester (34 weeks gestational age) Vaginal delivery (n = 1) ●○○○ Yue et al., 2020 [73] China n = 14 Mean maternal age 30.1 ± 3.4 Case series study Fever (n = 4) NR Third trimester (mean weeks gestational age 38 ± 0.4) Emergency cesarean (n = 13) ●●○○ Zeng et al., 2020 [68] China n = 33 Age: 24 to 34 years Case report Cough (n = 10) Fever on admission (n = 8) Fever (n = 5) Third trimester (≥31 weeks gestational age) Cesarean delivery because of meconium-stained amniotic fluid Cesarean delivery (n = 26) Natural childbirth (n = 7) ●●●○ Zhang et al., 2020 [69] China n = 16 Age: 24 to 34 years Retrospective study Cough (n = 3) Chest tightness (n = 3) Shortness of breath (n = 3) Diarrhea (n = 3) NR Third trimester (≥38 weeks gestational age) Cesarean section (n = 10) ●●○○ Zhu et al., 2020 [70] China n = 9 Mother of the twins (n = 1) Age: 25 to 34 years Retrospective study Fever (n = 7) Cough (n = 4) Diarrhea (n = 1) NR Third trimester (≥31 weeks gestational age) Cesarean section (n = 7) Vaginal delivery (n = 2) ●●○○ NR: Not reported; * Quality of evidence based on GRADE classification in four categories: Very low quality, low quality, moderate quality, or high quality. healthcare-08-00511-t002_Table 2Table 2 Comorbidities and complications in pregnant women diagnosed with COVID-19. Gestational Age Comorbidity Complications Second trimester Psoriasis [79] Severe hypertension [79] Coagulopathy [79] Preeclampsia [79] Third trimester Asthma [21,23,50,56] Chronic comorbidity [82] Chronic hypertension [22,23] Type 2 diabetes mellitus [18,21,22,23,26,75] Dysfunction of blood coagulation [64] Hepatitis B [9,43] History of frequent bacterial infections (sinusitis, skin infection, and bronchitis) during this pregnancy [40] Hypertension [26,35,41,43,63] Hypothyroidism [59,64,66] Polycystic ovary syndrome [66] Mild-intermittent asthma [22] Obesity [21,22,34,35,50,56,69,75] Obstructive sleep apnea [21] Polycystic ovary syndrome [43] Abnormal placenta (placenta previa) [70] Complete prior placenta [27] Complications in pregnancy ([73] Gestational diabetes [9,21,28,33,34,35,40,50,56,63,64,69] Gestational hypertension [9,21,25,56,64] Pneumonia secondary to COVID-19 [85] Sepsis [85] Maternal COVID-19 pneumonia [68] Intrauterine fetal distress [73] Placental detachment [27] Preeclampsia [25,28,50,63,69] Previous placenta [30] Severe preeclampsia [64] Second and third trimesters * Asthma [41,48] Cardiac disease [41] Diabetes [41] Hypertension [41] Obese [41] Overweight or obese [48] Type 2 diabetes [48] Gestational diabetes [41,48] Gestational hypertension [48] First, second, and third trimesters * Asthma [49] Autoimmune disease [55] Chronic hepatitis B virus infection [54] Chronic hypertension [49] Diabetes [49,54] Endocrine disease [55] Hypertension [54] Hypothyroidism [54] Metabolic diseases [55] Obesity [55] Gestational diabetes [49] Preeclampsia [49] * There was no stratification of comorbidity and complications for the gestational semester. healthcare-08-00511-t003_Table 3Table 3 Results for newborn placentas and breast milk that tested positive for SARS-CoV-2 after birth. First Author and Year Diagnosis Test Type of Delivery Positive COVID-19 Test Results NEWBORNS Alzamora et al., 2020 [18] Nasopharyngeal swab was obtained for SARS-CoV-2 RT-PCR Emergency cesarean section (n = 1) Nasopharyngeal swab, 16 h after delivery, was positive for SARS-CoV-2 RT-PCR, and immunoglobulin (Ig)-M and IgG for SARS-CoV-2: Negative Buonsenso et al., 2020 [24] RT-PCR Cesarean section (n = 1) SARS-CoV-2 positive at 15 days of life, although asymptomatic Facchetti et al., 2020 [83] SARS-CoV-2 RNA on nasopharyngeal swab Vaginal delivery was induced (n = 1) Resulted inconclusive (amplification of less than three genes), while it was positive 36 and 72 h after birth and at the age of 17 days Fenizia et al., 2020 [82] Nasopharyngeal newborn swab was obtained for SARS-CoV-2 RT-PCR after the baby was cleaned Vaginal delivery (n = 25) Caesarean section (n = 6) Viral RNA positive in newborns (n = 2) Ferrazzi et al., 2020 [33] RT-PCR (1) Elective cesarean section (n = 2) (2) Vaginal delivery (n = 1) (1) Newborns had a positive test for COVID-19 infection at days one and three, respectively (2) The first test for SARS-CoV-2 was equivocal a few hours after delivery, but positive three days later Hantoushzadeh et al., 2020 [36] SARS-CoV-2 NAT Cesarean section (n = 1) Negative on day 1 of life but converted to positive on day 7 of life with an accompanying lymphopenia (nadir white blood cell 8.9, with 26% lymphocytes) The neonate was intubated for prematurity, developed pneumonia at day of life 2 There was maternal death Knight et al., 2020 [41] Detection of viral RNA on polymerase chain reaction testing of blood or a nasopharyngeal swab or aspirate Cesarean section (n = 4) Vaginal birth (n = 2) Positive test <12 h of age (n = 6) Positive test ≥12 h of age 6 (n = 6) Kirtsman et al., 2020 [40] RT-PCR Placental swabs (both maternal and fetal sides) were obtained Placental tissue was sent for PCR and histopathologic examination Nasopharyngeal swabs were obtained from the neonate on the day of birth, day 2, and day 7, after thorough cleansing of the baby and before contact with the mother Cesarean section (n = 1) All 3 of the neonate’s nasopharyngeal swabs were positive for SARS-CoV-2 gene targets via RT-PCR testing; neonatal plasma tested positive on day 4, and stool was positive on day 7 Martínez-Perez et al., 2020 [50] SARS-CoV-2 RNA RT-PCR Vaginal delivery (n = 2) Cesarean section (n = 1) Three newborns tested within 6 h after birth had a positive SARS-CoV-2 RT-PCR result Repeat testing at 48 h was negative None developed COVID-19 symptoms within 10 days Patanè et al., 2020 [51] SARS-CoV-2 RNA RT-PCR Vaginal delivery (n = 1) Cesarean section (n = 1) (1) The newborn had positive NP swabs immediately at birth, after 24 h, and after 7 days; he remained asymptomatic (2) Neonatal NP swab was 60 negative at birth and turned positive on day 7, with no contact between mother and neonate during that period Savasi et al., 2020 [55] Pharyngeal swab sampled for SARS-CoV-2 Vaginal delivery (n = 3) Cesarean section (n = 1) Positive on the seventh day (n = 1) Schwartz et al., 2020 [76] Infant RT-PCR testing Cesarean section (n = 8) Spontaneous vaginal delivery (n = 1) Positive by RT-PCR for SARS-CoV-2 (n = 9): 1 h after delivery (n = 1) 2 h after delivery (n = 1) DOL 2 (n = 1) DOL 3 (n = 1) DOL 4 (n = 2) DOL 6 (n = 1) DOL 7 (n = 1) DOL 24 (n = 1) Sisman et al., 2020 [75] Nasopharyngeal swab by RT-PCR for SARS-CoV-2 at 24 and 48 h of life Vaginal delivery (n = 1) Positive by nasopharyngeal swab Vivanti et al., 2020 [74] Nasopharyngeal and rectal swabs were first collected after having cleaned the baby at 1 h of life, and they were tested with RT-PCR Blood and nonbronchoscopic bronchoalveolar lavage fluid were collected for RT-PCR Cesarean delivery (n = 1) Nasopharyngeal and rectal Blood and nonbronchoscopic bronchoalveolar lavage fluid Clear amniotic fluid was collected prior to rupture of membranes during cesarean section and tested positive for both the E and S genes of SARS-CoV-2 Zeng et al., 2020 [68] SARS-CoV-2 real-time reverse transcriptase–polymerase Cesarean section (n = 3) (1) Nasopharyngeal and anal swabs were positive for SARS-CoV-2 on days 2 and 4 of life (2) Nasopharyngeal and anal swabs were positive for SARS-CoV-2 on days 2 and 4 of life and negative on day 6 (3) Nasopharyngeal and anal swabs were positive for SARS-CoV-2 on days 2 and 4 of life and negative on day 7 Wang et al., 2020 [65] SARS-CoV-2 RNA RT-PCR Pharyngeal swab Emergency cesarean section (n = 1) The result of pharyngeal swab for SARS-CoV-2 was positive at 36 h after birth Yu et al., 2020 [67] RT-PCR for SARS-CoV-2 Cesarean section (n = 1) Nucleic acid test for the throat swab of one neonate (child of patient 1) was positive at 36 h after birth IgG Antibody Dong et al., 2020 [31] CT and RT-PCR nasopharyngeal swabs; and IgM and IgG antibody, cytokine, and other biochemistry tests in blood Vaginal secretions Cesarean section (n = 1) A neonate born to a mother with COVID-19 had elevated antibody levels (IgM) and abnormal cytokine test results 2 h after birth Nasopharyngeal swabs taken from 2 h to 16 days of age were negative Mother’s breast milk had a negative RT-PCR test result Fenizia et al., 2020 [82] Umbilical cord plasma: SARS-CoV-2 RT-PCR and SARS-CoV-2 IgG and IgM chemiluminescence immunoassay Vaginal delivery (n = 25) Caesarean section (n = 6) Viral RNA positive + IgG positive in umbilical cord plasma (n = 1) IgG positive in umbilical cord plasma (n = 10) IgM positive + IgG positive in umbilical cord plasma (n = 1) Umbilical Cord Fenizia et al., 2020 [82] Umbilical cord: SARS-CoV-2 RT-PCR Vaginal delivery (n = 25) Caesarean section (n = 6) Viral RNA positive in umbilical cord (n = 1) Vaginal Swab Fenizia et al., 2020 [82] Vaginal swab: SARS-CoV-2 RT-PCR Vaginal delivery (n = 25) Caesarean section (n = 6) Viral RNA positive in vaginal swab (n = 1) Yang et al., 2020 [64] RT-PCR for SARS-CoV-2 SARS-CoV-2IgM/IgG antibodies rapid test kit Cesarean section (n = 1) Premature rupture of fetal membranes Elevated IgM level of SARS-CoV-2 2 h after her birth Testing on her nasopharyngeal swab was negative (tested twice) Symptomatic Cases Fan et al., 2020 [32] RT-PCR nasopharyngeal swab, maternal serum, placental tissues, umbilical cord blood, amniotic fluid, vaginal swabs, and breast milk Cesarean section (n = 2) Symptoms, suspected case: Two babies showed symptoms but failed to detect SARS-CoV-2 in any of the samples, including the newborn’s nasopharyngeal swab, maternal serum, placental tissues, umbilical cord blood, amniotic fluid, vaginal swabs, and breast milk Gidlöf et al., 2020 [35] RT-PCR Emergency cesarean section (n = 2) Twins symptoms, suspected cases: At 22 min after delivery developed breathing problems On the second day, she had a cyanotic attack while feeding Both twins had negative nasopharyngeal COVID-19 tests taken at 34 h and 4½ days of age COVID-19 tests performed on breast milk and maternal vaginal secretion on the fifth day were also negative Placenta Algarroba et al., 2020 Electron microscopy Cesarean delivery A single virion was visible invading a syncytiotrophoblast A single virion was also visualized in a microvillus Baud et al., 2020 [20] Maternal—RT-PCR Deep nasopharyngeal Deep nasopharyngeal control Vagina Blood Fetus—RT-PCR Umbilical cord blood Amniotic fluid negative sterile Fetal armpit Placental submembrane Placental cotyledon Fetal anus Fetal liver Fetal thymus Fetal lung Vaginal delivery (n = 1) Placental submembrane—positive sterile Placental cotyledon—positive Facchetti et al., 2020 [83] Histological, immunohistochemical, in situ SARS-CoV-2 RNA, RNA in situ hybridization and electron microscopy Vaginal delivery was induced (n = 1)—third trimester Placenta: Tested positive for SARS-CoV-2, after detecting the presence of S-protein-specific transcripts by RNA-in situ hybridization; immunostains for SARS-CoV-2 proteins showed positivity in the cytoplasm of the syncytiotrophoblast for both S-protein and n-protein Fenizia et al., 2020 [82] SARS-CoV-2 RT-PCR Vaginal delivery (n = 25) Caesarean section (n = 6) Third trimester Viral RNA positive in placenta (n = 2) Ferraiolo et al., 2020 SARS-CoV-2 RT-PCR Urgent cesarean section (n = 1)—third trimester The definitive histological analysis of the placenta did not describe substantial macroscopic alterations, except for mild subchorionic deposition of fibrin and for the presence of a single ischemic area in the thickness of the chorionic disc Hosier et al., 2020 SARS-CoV-2 RT-PCR Whole-genome sequenced Histological examination Electron microscopy Urgent cesarean section (n = 1)—second trimester Placenta and umbilical cord were positive for SARS On histological examination, SARS-CoV-2 localized predominantly to the syncytiotrophoblast cells of the placenta Analysis of the placental region adjacent to the umbilical cord identified virus particles within the cytosol of placental cells consistent with the size and appearance of SARS-CoV-2 Penfield et al., 2020 [52] SARS-CoV-2 RNA RT-PCR Cesarean section (n = 3) Infected placentas (n = 1) or membrane swabs (n = 2) Patanè et al., 2020 [51] SARS-CoV-2 RNA RT-PCR Vaginal delivery (n = 1) Cesarean section (n = 1) SARS-CoV-2 RNA in the placentas Vivanti et al., 2020 [74] SARS-CoV-2 RNA RT-PCR Cesarean delivery (n = 1) Third trimester Placental infection as positive for SARS-CoV-2 RNA Breast Milk Costa et al., 2020 [84] SARS-CoV-2 RT-PCR in six breast milk samples Cesarean delivery (n = 2)—third trimester Three of six breast milk samples (50%) had a cycle threshold value <40 (the value interpreted as positive for SARS-CoV-2 RNA), indicating that patient 1 excreted virus in her breast milk, albeit intermittently (n = 1) Fenizia et al., 2020 [82] Five days after delivery (T2), transitional/mature breast milk samples were collected from all breastfeeding women Diagnosis test SARS-CoV-2 RT-PCR and SARS-CoV-2 IgG and IgM chemiluminescence immunoassay Vaginal delivery (n = 25) Caesarean section (n = 6) Third trimester Viral RNA positive and IgM positive in breast milk (n = 1) Wu et al., 2020 [61] SARS-CoV-2 RNA RT-PCR—1st day after delivery Breast milk samples from three women were collected on the 1st, 6th, and 27th days after delivery Vaginal swabs Neonatal throat and anal swabs were collected on the 1st and 3rd days after birth Caesarean section (n = 4) Natural delivery (n = 1) Detection of SARS-CoV-2 in breast milk RT-PCR: Reverse transcriptase—polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; DOL: Days of life. ==== Refs References 1. Li Q. Guan X. Wu P. Wang X. Zhou L. Tong Y. Ren R. Leung K.S.M. Lau E.H.Y. Wong J.Y. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia N. Engl. J. Med. 2020 382 1199 1207 10.1056/NEJMoa2001316 31995857 2. The Lancet Infectious Diseases COVID-19, a pandemic or not? Lancet Infect. Dis. 2020 20 383 10.1016/S1473-3099(20)30180-8 32178762 3. Guan W.J. Ni Z.Y. Hu Y. Liang W.H. Ou C.Q. He J.X. Liu L. Shan H. Lei C.L. Hui D.S.C. Clinical Characteristics of Coronavirus Disease 2019 in China N. Engl. J. Med. 2020 382 1708 1720 10.1056/NEJMoa2002032 32109013 4. Giwa A.L. Desai A. Duca A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians Emerg. Med. Pract. 2020 22 1 28 5. Khan S. Peng L. Siddique R. Nabi G. Nawsherwan Xue M. Liu J. Han G. Impact of COVID-19 infection on pregnancy outcomes and the risk of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth Infect. Control. Hosp. Epidemiol. 2020 41 748 750 10.1017/ice.2020.84 32279693 6. Qiao J. What are the risks of COVID-19 infection in pregnant women? Lancet 2020 395 760 762 10.1016/S0140-6736(20)30365-2 32151334 7. Lee D.H. Lee J. Kim E. Woo K. Park H.Y. An J. Emergency cesarean section on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed patient Korean J. Anesthesiol. 2020 73 347 351 10.4097/kja.20116 32229802 8. Favre G. Pomar L. Qi X. Nielsen-Saines K. Musso D. Baud D. Guidelines for pregnant women with suspected SARS-CoV-2 infection Lancet Infect. Dis. 2020 20 652 653 10.1016/S1473-3099(20)30157-2 32142639 9. Liu H. Liu F. Li J. Zhang T. Wang D. Lan W. Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children J. Infect. 2020 80 e7 e13 10.1016/j.jinf.2020.03.007 32171865 10. Walker K.F. O’Donoghue K. Grace N. Dorling J. Comeau J.L. Li W. Thornton J.G. Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: A systematic review and critical analysis BJOG 2020 127 1324 1336 10.1111/1471-0528.16362 32531146 11. Lopes de Sousa Á.F. Carvalho H.E.F.d. Oliveira L.B.d. Schneider G. Camargo E.L.S. Watanabe E. de Andrade D. Fernandes A.F.C. Mendes I.A.C. Fronteira I. Effects of COVID-19 Infection during Pregnancy and Neonatal Prognosis: What Is the Evidence? Int. J. Environ. Res. Public Health 2020 17 4176 10.3390/ijerph17114176 32545378 12. Smith V. Seo D. Warty R. Payne O. Salih M. Chin K.L. Ofori-Asenso R. Krishnan S. da Silva Costa F. Vollenhoven B. Maternal and neonatal outcomes associated with COVID-19 infection: A systematic review PLoS ONE 2020 15 e0234187 10.1371/journal.pone.0234187 32497090 13. Yang Z. Wang M. Zhu Z. Liu Y. Coronavirus disease 2019 (COVID-19) and pregnancy: A systematic review J. Matern. Fetal Neonatal Med. 2020 10.1080/14767058.2020.1759541 32354293 14. Moher D. Liberati A. Tetzlaff J. Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement Int. J. Surg. 2010 8 336 341 10.1016/j.ijsu.2010.02.007 20171303 15. Soares C.B. Hoga L.A. Peduzzi M. Sangaleti C. Yonekura T. Silva D.R. Integrative review: Concepts and methods used in nursing Rev. Esc. Enferm. USP 2014 48 335 345 10.1590/S0080-6234201400002000020 24918895 16. Guyatt G. Oxman A.D. Akl E.A. Kunz R. Vist G. Brozek J. Norris S. Falck-Ytter Y. Glasziou P. DeBeer H. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables J. Clin. Epidemiol. 2011 64 383 394 10.1016/j.jclinepi.2010.04.026 21195583 17. Balshem H. Helfand M. Schünemann H.J. Oxman A.D. Kunz R. Brozek J. Vist G.E. Falck-Ytter Y. Meerpohl J. Norris S. GRADE guidelines: 3. Rating the quality of evidence J. Clin. Epidemiol. 2011 64 401 406 10.1016/j.jclinepi.2010.07.015 21208779 18. Alzamora M.C. Paredes T. Caceres D. Webb C.M. Valdez L.M. La Rosa M. Severe COVID-19 during pregnancy and possible vertical transmission Am. J. Perinatol. 2020 37 861 32305046 19. Baud D. Giannoni E. Pomar L. Qi X. Nielsen-Saines K. Musso D. Favre G. COVID-19 in pregnant women–Authors’ reply Lancet Infect. Dis. 2020 20 654 10.1016/S1473-3099(20)30192-4 32197096 20. Baud D. Greub G. Favre G. Gengler C. Jaton K. Dubruc E. Pomar L. Second-trimester miscarriage in a pregnant woman with SARS-CoV-2 infection JAMA 2020 323 2198 2200 10.1001/jama.2020.7233 32352491 21. Blitz M.J. Rochelson B. Minkoff H. Meirowitz N. Prasannan L. London V. Rafael T.J. Chakravarthy S. Bracero L.A. Wasden S.W. Maternal Mortality Among Women with COVID-19 Admitted to the Intensive Care Unit Am. J. Obstet. Gynecol. 2020 223 595 599.e5 10.1016/j.ajog.2020.06.020 32553910 22. Breslin N. Baptiste C. Gyamfi-Bannerman C. Miller R. Martinez R. Bernstein K. Ring L. Landau R. Purisch S. Friedman A.M. COVID-19 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals Am. J. Obstet Gynecol MFM 2020 2 100118 10.1016/j.ajogmf.2020.100118 32292903 23. Breslin N. Baptiste C. Miller R. Fuchs K. Goffman D. Gyamfi-Bannerman C. D’Alton M. COVID-19 in pregnancy: Early lessons Am. J. Obstet. Gynecol. MFM 2020 2 100111 10.1016/j.ajogmf.2020.100111 32518902 24. Buonsenso D. Costa S. Sanguinetti M. Cattani P. Posteraro B. Marchetti S. Carducci B. Lanzone A. Tamburrini E. Vento G. Neonatal late onset infection with severe acute respiratory syndrome Coronavirus 2 Am. J. Perinatol. 2020 37 869 872 32359227 25. Chen H. Guo J. Wang C. Luo F. Yu X. Zhang W. Li J. Zhao D. Xu D. Gong Q. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records Lancet 2020 395 809 815 10.1016/S0140-6736(20)30360-3 32151335 26. Chen R. Zhang Y. Huang L. Cheng B.H. Xia Z.Y. Meng Q.T. Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: A case series of 17 patients Can. J. Anaesth. J. Can. d’anesthesie 2020 67 655 663 10.1007/s12630-020-01630-7 27. Chen S. Huang B. Luo D.J. Li X. Yang F. Zhao Y. Nie X. Huang B.X. Pregnant women with new coronavirus infection: A clinical characteristics and placental pathological analysis of three cases Zhonghua Bing Li Xue Za Zhi Chin. J. Pathol. 2020 49 E005 28. Chen S. Liao E. Cao D. Gao Y. Sun G. Shao Y. Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia J. Med. Virol. 2020 92 1556 1561 10.1002/jmv.25789 32222119 29. Chen X. Li Y. Wang J. Cai H. Cao H. Sheng J. Pregnant women complicated with COVID-19: A clinical analysis of 3 cases Zhejiang Da Xue Xue Bao. Yi Xue Ban J. of Zhejiang Univ. Med. Sci. 2020 49 240 244 30. Chen Y. Peng H. Wang L. Zhao Y. Zeng L. Gao H. Liu Y. Infants Born to Mothers with a New Coronavirus (COVID-19) Front. Pediatr. 2020 8 104 10.3389/fped.2020.00104 32266184 31. Dong L. Tian J. He S. Zhu C. Wang J. Liu C. Yang J. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn JAMA 2020 323 1846 1848 10.1001/jama.2020.4621 32215581 32. Fan C. Lei D. Fang C. Li C. Wang M. Liu Y. Bao Y. Sun Y. Huang J. Guo Y. Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We Worry? Clin. Infect. Dis 2020 10.1093/cid/ciaa226 32182347 33. Ferrazzi E. Frigerio L. Savasi V. Vergani P. Prefumo F. Barresi S. Bianchi S. Ciriello E. Facchinetti F. Gervasi M.T. Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: A retrospective analysis BJOG 2020 127 1116 1121 10.1111/1471-0528.16278 32339382 34. Fontanella F. Hannes S. Keating N. Martyn F. Browne I. Briet J. McAuliffe F.M. Baalman J.H. COVID-19 infection during the third trimester of pregnancy: Current clinical dilemmas Eur J. Obstet. Gynecol. Reprod. Biol. 2020 251 268 271 10.1016/j.ejogrb.2020.05.053 32505514 35. Gidlöf S. Savchenko J. Brune T. Josefsson H. COVID-19 in pregnancy with comorbidities: More liberal testing strategy is needed Acta Obstet. Et Gynecol. Scand. 2020 99 948 949 10.1111/aogs.13862 32249924 36. Hantoushzadeh S. Shamshirsaz A.A. Aleyasin A. Seferovic M.D. Aski S.K. Arian S.E. Pooransari P. Ghotbizadeh F. Aalipour S. Soleimani Z. Maternal death due to COVID-19 Am. J. Obstet. Gynecol. MFM 2020 223 109.e1 109.e16 10.1016/j.ajog.2020.04.030 37. Iqbal S.N. Overcash R. Mokhtari N. Saeed H. Gold S. Auguste T. Mirza M.U. Ruiz M.E. Chahine J.J. Waga M. An Uncomplicated Delivery in a Patient with Covid-19 in the United States N. Engl. J. Med. 2020 382 e34 10.1056/NEJMc2007605 32237670 38. Kalafat E. Yaprak E. Cinar G. Varli B. Ozisik S. Uzun C. Azap A. Koc A. Lung ultrasound and computed tomographic findings in pregnant woman with COVID-19 Ultrasound Obstet. Gynecol. 2020 55 835 837 10.1002/uog.22034 32249471 39. Karami P. Naghavi M. Feyzi A. Aghamohammadi M. Novin M.S. Mobaien A. Qorbanisani M. Karami A. Norooznezhad A.H. WITHDRAWN: Mortality of a pregnant patient diagnosed with COVID-19: A case report with clinical, radiological, and histopathological findings Travel Med. Infect. Dis. 2020 101665 10.1016/j.tmaid.2020.101665 32283217 40. Kirtsman M. Diambomba Y. Poutanen S.M. Malinowski A.K. Vlachodimitropoulou E. Parks W.T. Erdman L. Morris S.K. Shah P.S. Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection Can. Med. Assoc. J. 2020 192 E647 E650 10.1503/cmaj.200821 32409520 41. Knight M. Bunch K. Vousden N. Morris E. Simpson N. Gale C. O’Brien P. Quigley M. Brocklehurst P. Kurinczuk J.J. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: National population-based cohort study BMJ (Clin. Res. Ed.) 2020 369 m2107 10.1136/bmj.m2107 32513659 42. Li J. Wang Y. Zeng Y. Song T. Pan X. Jia M. He F. Hou L. Li B. He S. Critically ill pregnant patient with COVID-19 and neonatal death within two hours of birth Int. J. Gynecol. Obstet. 2020 150 126 128 10.1002/ijgo.13189 32369616 43. Li N. Han L. Peng M. Lv Y. Ouyang Y. Liu K. Yue L. Li Q. Sun G. Chen L. Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: A case-control study Clin. Infect. Dis. 2020 10.1101/2020.03.10.20033605 44. Li Y. Zhao R. Zheng S. Chen X. Wang J. Sheng X. Zhou J. Cai H. Fang Q. Yu F. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China Emerg. Infect. Dis. 2020 26 1335 1336 10.3201/eid2606.200287 32134381 45. Liao X. Yang H. Kong J. Yang H. Chest CT Findings in a Pregnant Patient with 2019 Novel Coronavirus Disease Balk. Med. J. 2020 10.4274/balkanmedj.galenos.2020.2020.3.89 46. Liu D. Li L. Wu X. Zheng D. Wang J. Yang L. Zheng C. Pregnancy and Perinatal Outcomes of Women with Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis AJR Am. J. Roentgenol. 2020 215 127 132 10.2214/AJR.20.23072 32186894 47. Liu W. Wang Q. Zhang Q. Chen L. Chen J. Zhang B. Lu Y. Wang S. Xia L. Huang L. Coronavirus disease 2019 (COVID-19) during pregnancy: A case series Available online: https://www.preprints.org/manuscript/202002.0373/v1. (accessed on 18 November 2020) 48. Lokken E.M. Walker C.L. Delaney S. Kachikis A. Kretzer N.M. Erickson A. Resnick R. Vanderhoeven J. Hwang J.K. Barnhart N. Clinical Characteristics of 46 Pregnant Women with a SARS-CoV-2 Infection in Washington State Am. J. Obstet. Gynecol. MFM 2020 10.1016/j.ajog.2020.05.031 49. London V. McLaren R. Jr. Atallah F. Cepeda C. McCalla S. Fisher N. Stein J.L. Haberman S. Minkoff H. The Relationship between Status at Presentation and Outcomes among Pregnant Women with COVID-19 Am. J. Perinatol. 2020 37 991 994 10.1055/s-0040-1712164 32428964 50. Martínez-Perez O. Vouga M. Cruz Melguizo S. Forcen Acebal L. Panchaud A. Muñoz-Chápuli M. Baud D. Association Between Mode of Delivery Among Pregnant Women With COVID-19 and Maternal and Neonatal Outcomes in Spain JAMA 2020 324 296 10.1001/jama.2020.10125 32511673 51. Patanè L. Morotti D. Giunta M.R. Sigismondi C. Piccoli M.G. Frigerio L. Mangili G. Arosio M. Cornolti G. Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth Am. J. Obstet. Gynecol. MFM 2020 2 100145 10.1016/j.ajogmf.2020.100145 32427221 52. Penfield C.A. Brubaker S.G. Limaye M.A. Lighter J. Ratner A.J. Thomas K.M. Meyer J. Roman A.S. Detection of SARS-COV-2 in Placental and Fetal Membrane Samples Am. J. Obstet. Gynecol. MFM 2020 2 100133 10.1016/j.ajogmf.2020.100133 32391518 53. Peng Z. Wang J. Mo Y. Duan W. Xiang G. Yi M. Bao L. Shi Y. Unlikely SARS-CoV-2 vertical transmission from mother to child: A case report J. Infect. Public Health 2020 13 818 820 10.1016/j.jiph.2020.04.004 32305459 54. Qiancheng X. Jian S. Lingling P. Lei H. Xiaogan J. Weihua L. Gang Y. Shirong L. Zhen W. GuoPing X. Coronavirus disease 2019 in pregnancy Int. J. Infect. Dis. 2020 95 376 383 10.1016/j.ijid.2020.04.065 32353549 55. Savasi V.M. Parisi F. Patanè L. Ferrazzi E. Frigerio L. Pellegrino A. Spinillo A. Tateo S. Ottoboni M. Veronese P. Clinical Findings and Disease Severity in Hospitalized Pregnant Women with Coronavirus Disease 2019 (COVID-19) Obstet. Gynecol. 2020 136 252 258 10.1097/AOG.0000000000003979 32433453 56. Sentilhes L. De Marcillac F. Jouffrieau C. Kuhn P. Thuet V. Hansmann Y. Ruch Y. Fafi-Kremer S. Deruelle P. COVID-19 in pregnancy was associated with maternal morbidity and preterm birth Am. J. Obstet. Gynecol. MFM 2020 10.1016/j.ajog.2020.06.022 57. Siying Z. Juanjuan G. Yuming C. Huijun C. Dan X. Jiafu L. Yuanzhen Z. A case of new coronavirus infection in perinatal period Chin. J. Perinat. Med. 2020 23 85 90 58. Wang S. Guo L. Chen L. Liu W. Cao Y. Zhang J. Feng L. A case report of neonatal COVID-19 infection in China Clin. Infect. Dis. 2020 71 853 857 10.1093/cid/ciaa225 32161941 59. Wang X. Zhou Z. Zhang J. Zhu F. Tang Y. Shen X. A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery Clin. Infect. Dis. 2020 71 844 846 10.1093/cid/ciaa200 32119083 60. Wu X. Sun R. Chen J. Xie Y. Zhang S. Wang X. Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia Int. J. Gynaecol. Obstet. 2020 10.1002/ijgo.13165 61. Wu Y. Liu C. Dong L. Zhang C. Chen Y. Liu J. Zhang C. Duan C. Zhang H. Mol B.W. Coronavirus disease 2019 among pregnant Chinese women: Case series data on the safety of vaginal birth and breastfeeding BJOG 2020 127 1109 1115 10.1111/1471-0528.16276 32369656 62. Xiong X. Wei H. Zhang Z. Chang J. Ma X. Gao X. Chen Q. Pang Q. Vaginal Delivery Report of a Healthy Neonate Born to a Convalescent Mother with COVID-19 J. Med. Virol. 2020 92 1657 1659 10.1002/jmv.25857 32275072 63. Yan J. Guo J. Fan C. Juan J. Yu X. Li J. Feng L. Li C. Chen H. Qiao Y. Coronavirus disease 2019 in pregnant women: A report based on 116 cases Am. J. Obstet. Gynecol. MFM 2020 10.1016/j.ajog.2020.04.014 32335053 64. Yang H. Hu B. Zhan S. Yang L.Y. Xiong G. Effects of SARS-CoV-2 infection on pregnant women and their infants: A retrospective study in Wuhan, China Arch. Pathol. Lab. Med. 2020 10.5858/arpa.2020-0232-SA 32422078 65. Yang P. Wang X. Liu P. Wei C. He B. Zheng J. Zhao D. Clinical characteristics and risk assessment of newborns born to mothers with COVID-19 J. Clin. Virol. 2020 127 104356 10.1016/j.jcv.2020.104356 32302955 66. Yu N. Li W. Kang Q. Xiong Z. Wang S. Lin X. Liu Y. Xiao J. Liu H. Deng D. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: A retrospective, single-centre, descriptive study Lancet Infect. Dis. 2020 10.1016/S1473-3099(20)30176-6 67. Yu Y. Fan C. Bian J. Shen Y. Severe COVID-19 in a pregnant patient admitted to hospital in Wuhan Int. J. Gynecol. Obstet. 2020 150 262 263 10.1002/ijgo.13232 68. Zeng L. Xia S. Yuan W. Yan K. Xiao F. Shao J. Zhou W. Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China JAMA Pediatr. 2020 174 722 10.1001/jamapediatrics.2020.0878 32215598 69. Zhang L. Jiang Y. Wei M. Cheng B.H. Zhou X.C. Li J. Tian J.H. Dong L. Hu R.H. Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province Zhonghua Fu Chan Ke Za Zhi 2020 55 E009 70. Zhu H. Wang L. Fang C. Peng S. Zhang L. Chang G. Xia S. Zhou W. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia Transl. Pediatrics 2020 9 51 60 10.21037/tp.2020.02.06 71. Lowe B. Bopp B. COVID-19 vaginal delivery—A case report Aust. N. Z. J. Obstet. Gynaecol. 2020 60 465 466 10.1111/ajo.13173 32294229 72. Hijona Elósegui J.J. Carballo García A.L. Fernández Risquez A.C. Bermúdez Quintana M. Expósito Montes J.F. Does the maternal-fetal transmission of SARS-CoV-2 occur during pregnancy? Rev. Clin. Esp. 2020 10.1016/j.rce.2020.06.001 32546368 73. Yue L. Han L. Li Q. Zhong M. Wang J. Wan Z. Chu C. Zeng Y. Peng M. Yang L. Anaesthesia and infection control in cesarean section of pregnant women with coronavirus disease 2019 (COVID-19) medRxiv 2020 10.1016/S1473-3099(20)30180-8 74. Vivanti A.J. Vauloup-Fellous C. Prevot S. Zupan V. Suffee C. Do Cao J. Benachi A. De Luca D. Transplacental transmission of SARS-CoV-2 infection Nat. Commun. 2020 11 3572 10.1038/s41467-020-17436-6 32665677 75. Sisman J. Jaleel M.A. Moreno W. Rajaram V. Collins R.R.J. Savani R.C. Rakheja D. Evans A.S. Intrauterine Transmission of SARS-COV-2 Infection in a Preterm Infant Pediatric Infect. Dis. J. 2020 39 e265 e267 10.1097/INF.0000000000002815 32658097 76. Schwartz D.A. Mohagheghi P. Beigi B. Zafaranloo N. Moshfegh F. Yazdani A. Spectrum of neonatal COVID-19 in Iran: 19 infants with SARS-CoV-2 perinatal infections with varying test results, clinical findings and outcomes J. Matern.-Fetal Neonatal Med. 2020 1 10 10.1080/14767058.2020.1797672 77. Pereira A. Cruz-Melguizo S. Adrien M. Fuentes L. Marin E. Perez-Medina T. Clinical course of coronavirus disease-2019 in pregnancy Acta Obstet. Et Gynecol. Scand. 2020 99 839 847 10.1111/aogs.13921 78. Lv Y. Gu B. Chen Y. Hu S. Ruan T. Xu G. Ding J. Xu X. Shen X. No intrauterine vertical transmission in pregnancy with COVID-19: A case report J. Infect. Chemother. 2020 26 1313 1315 10.1016/j.jiac.2020.07.015 32859496 79. Hosier H. Farhadian S.F. Morotti R.A. Deshmukh U. Lu-Culligan A. Campbell K.H. Yasumoto Y. Vogels C.B. Casanovas-Massana A. Vijayakumar P. SARS-CoV-2 infection of the placenta J. Clin. Investig. 2020 130 4947 4953 10.1172/JCI139569 32573498 80. Marín Gabriel M. Malalana Martínez A.M. Marín Martínez M.E. Anel Pedroche J. Negative Transmission of SARS-CoV-2 to Hand-Expressed Colostrum from SARS-CoV-2-Positive Mothers Breastfeed. Med. 2020 15 492 494 10.1089/bfm.2020.0183 32644841 81. Ferraiolo A. Barra F. Kratochwila C. Paudice M. Vellone V.G. Godano E. Varesano S. Noberasco G. Ferrero S. Arioni C. Report of Positive Placental Swabs for SARS-CoV-2 in an Asymptomatic Pregnant Woman with COVID-19 Medicina 2020 56 306 10.3390/medicina56060306 82. Fenizia C. Biasin M. Cetin I. Vergani P. Mileto D. Spinillo A. Gismondo M.R. Perotti F. Callegari C. Mancon A. Analysis of SARS-CoV-2 vertical transmission during pregnancy Nat. Commun. 2020 11 5128 10.1038/s41467-020-18933-4 33046695 83. Facchetti F. Bugatti M. Drera E. Tripodo C. Sartori E. Cancila V. Papaccio M. Castellani R. Casola S. Boniotti M.B. SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta EBioMedicine 2020 59 10.1016/j.ebiom.2020.102951 84. Costa S. Posteraro B. Marchetti S. Tamburrini E. Carducci B. Lanzone A. Valentini P. Buonsenso D. Sanguinetti M. Vento G. Excretion of SARS-CoV-2 in human breast milk Clin. Microbiol. Infect. 2020 26 1430 1432 10.1016/j.cmi.2020.05.027 32502644 85. Algarroba G.N. Rekawek P. Vahanian S.A. Khullar P. Palaia T. Peltier M.R. Chavez M.R. Vintzileos A.M. Visualization of severe acute respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy Am. J. Obstet. Gynecol. MFM 2020 223 275 278 10.1016/j.ajog.2020.05.023 32405074 86. Zeng Y. Lin L. Yan Q. Wei W. Yang B.X. Huang R. He F. Chen D. Update on clinical outcomes of women with COVID-19 during pregnancy Int. J. Gynaecol. Obstet. 2020 150 264 266 10.1002/ijgo.13236 32438521 87. Wan S. Li M. Ye Z. Yang C. Cai Q. Duan S. Song B. CT Manifestations and Clinical Characteristics of 1115 Patients with Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-analysis Acad. Radiol. 2020 27 910 921 10.1016/j.acra.2020.04.033 32505599 88. Celik O. Saglam A. Baysal B. Derwig I.E. Celik N. Ak M. Aslan S.N. Ulas M. Ersahin A. Tayyar A.T. Factors preventing materno-fetal transmission of SARS-CoV-2 Placenta 2020 97 1 5 10.1016/j.placenta.2020.05.012 32501218 89. Mahyuddin A.P. Kanneganti A. Wong J. Dimri P.S. Su L.L. Biswas A. Illanes S.E. Mattar C. Huang R.-J. Choolani M. Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV-2 Prenat. Diagn 2020 10.1002/pd.5765 90. Dashraath P. Wong J.L.J. Lim M.X.K. Lim L.M. Li S. Biswas A. Choolani M. Mattar C. Su L.L. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy Am. J. Obstet. Gynecol. MFM 2020 222 521 531 10.1016/j.ajog.2020.03.021 91. Rasmussen S.A. Jamieson D.J. Caring for Women Who Are Planning a Pregnancy, Pregnant, or Postpartum During the COVID-19 Pandemic JAMA 2020 324 190 10.1001/jama.2020.8883 32501505